Literature DB >> 10698061

Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods.

A Buck1, P M Gucker, R D Schönbächler, M Arigoni, S Kneifel, F X Vollenweider, S M Ametamey, C Burger.   

Abstract

[11C](+)McN-5652 is an established positron emission tomography tracer used to assess serotonergic transporter density. Several methods have been used to analyze [11C](+)McN-5652 data; however, no evaluation of candidate methods has been published in detail yet. In this study, compartmental modeling using a one-tissue compartment model (K1, k2"), a two-tissue compartment model (K1 to k4), and a noncompartmental method that relies on a reference region devoid of specific binding sites were assessed. Because of its low density of serotonergic transporters, white matter was chosen as reference. Parameters related to transporter density were the total distribution volume DV" (= K1/k2", one tissue compartment), DVtot, (=K1/k1' (1 + k3/k4), two tissue compartments), and Rv (= k3'/k4, noncompartmental method). The DV", DVtot, and Rv values extended over a similar range and reflected the known pattern of serotonergic transporters. However, all parameters related to transporter density were markedly confounded by nonspecific binding. With regard to K1, the one-tissue compartment model yielded markedly lower values, which were, however, more stable. The minimal study duration needed to determine stable values for the distribution volume was approximately 60 minutes. The choice of the method to analyze [11C](+)McN-5652 data depends on the situation. Parametric maps of Rv are useful if no information on K1 is needed. If compartmental modeling is chosen, both the one- and the two-tissue compartment models have advantages. The one-tissue compartment model underestimates K1 but yields more robust values. The distribution volumes calculated with both models contain a similar amount of information. None of the parameters reflected serotonergic transporter density in a true quantitative manner, as all were confounded by nonspecific binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698061     DOI: 10.1097/00004647-200002000-00005

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  13 in total

1.  PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study.

Authors:  Wen-Sheng Huang; San-Yuan Huang; Pei-Shen Ho; Kuo-Hsing Ma; Ya-Yao Huang; Chin-Bin Yeh; Ren-Syuan Liu; Cheng-Yi Cheng; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

2.  Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans.

Authors:  Swen Hesse; Peter Brust; Peter Mäding; Georg-Alexander Becker; Marianne Patt; Anita Seese; Dietlind Sorger; Jörg Zessin; Philipp M Meyer; Donald Lobsien; Sven Laudi; Bernd Habermann; Frank Füchtner; Julia Luthardt; Anke Bresch; Jörg Steinbach; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-17       Impact factor: 9.236

3.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

4.  Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Authors:  Zsolt Szabo; Una D McCann; Alan A Wilson; Ursula Scheffel; Taofeek Owonikoko; William B Mathews; Hayden T Ravert; John Hilton; Robert F Dannals; George A Ricaurte
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

Review 5.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

Authors:  Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

6.  Synthesis, radiolabeling and baboon SPECT imaging of 2beta-carbomethoxy-3beta-(3'-[(123)I]iodophenyl)tropane ([(123)I]YP256) as a serotonin transporter radiotracer.

Authors:  Frederic Bois; Ronald M Baldwin; Louis Amici; Mohammed S Al-Tikriti; Nora Kula; Ross Baldessarini; Robert B Innis; Julie K Staley; Gilles D Tamagnan
Journal:  Nucl Med Biol       Date:  2008-01       Impact factor: 2.408

Review 7.  Imaging phenotypes of major depressive disorder: genetic correlates.

Authors:  J B Savitz; W C Drevets
Journal:  Neuroscience       Date:  2009-04-07       Impact factor: 3.590

8.  Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans.

Authors:  Christopher J Endres; Martin G Pomper; Michelle James; Ovsev Uzuner; Dima A Hammoud; Crystal C Watkins; Aaron Reynolds; John Hilton; Robert F Dannals; Michael Kassiou
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

9.  Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain.

Authors:  Jonathon A Nye; John R Votaw; Nachwa Jarkas; David Purselle; Vernon Camp; James D Bremner; Clinton D Kilts; Charles B Nemeroff; Mark M Goodman
Journal:  J Nucl Med       Date:  2008-12       Impact factor: 10.057

10.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.

Authors:  R Thomasius; K Petersen; R Buchert; B Andresen; P Zapletalova; L Wartberg; B Nebeling; A Schmoldt
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.